Literature DB >> 17899274

Identification and classification of hereditary nonpolyposis colorectal cancer (Lynch syndrome): adapting old concepts to recent advancements. Report from the Italian Association for the study of Hereditary Colorectal Tumors Consensus Group.

Maurizio Ponz de Leon1, Lucio Bertario, Maurizio Genuardi, Giovanni Lanza, Cristina Oliani, Guglielmina Nadia Ranzani, Giovanni Battista Rossi, Liliana Varesco, Tiziana Venesio, Alessandra Viel.   

Abstract

Knowledge about hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome clearly evolved during the last 10 to 15 years much more rapidly than in the past century. Consequently, long-established concepts and attitudes that held for many years should now be changed or updated. With regard to classification, we suggest maintaining the eponym "Lynch syndrome" for families that have a well-documented deficiency of the DNA mismatch repair system, whereas "clinical hereditary nonpolyposis colorectal cancer" should be reserved for those families that meet the Amsterdam criteria but without evidence of mismatch repair impairment. Any family (or individual) meeting one or more of the Bethesda criteria can be considered as suspected HNPCC. For the identification of hereditary colorectal cancer molecular screening or the pedigree analysis show advantages and disadvantages; the ideal would be to combine the two approaches. Diffusion of the microsatellite instability test and of immunohistochemistry in the pathology laboratories might render in the immediate future molecular screening more realistic. Strict endoscopic surveillance of family members at risk (with first colonoscopy at age 20-25 years and then every 2-3 years) is needed only in families with documented alterations of the DNA mismatch repair. To a certain extent, our conclusions were similar to the recently proposed "European guidelines for the clinical management of HNPCC," although we prefer the term "clinical hereditary nonpolyposis colorectal cancer," instead of familial colorectal cancer, for families meeting the Amsterdam criteria but not having evidence of mismatch repair impairment.

Entities:  

Mesh:

Year:  2007        PMID: 17899274     DOI: 10.1007/s10350-007-9071-9

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  7 in total

1.  Inherited colorectal cancer syndromes.

Authors:  Robert Gryfe
Journal:  Clin Colon Rectal Surg       Date:  2009-11

2.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

3.  Extracolonic manifestations of lynch syndrome.

Authors:  Brian J Bansidhar
Journal:  Clin Colon Rectal Surg       Date:  2012-06

4.  Lynch syndrome in a predominantly Afrocentric population: a clinicopathological and genetic study.

Authors:  Joseph M Plummer; Sheray N Chin; Melyssa Aronson; Rondell P Graham; Nadia P Williams; Bharati Bapat; Gillian Wharfe; Aaron Pollett; Steven Gallinger
Journal:  Can J Surg       Date:  2012-10       Impact factor: 2.089

5.  Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites.

Authors:  Joo Hoon Kim; Sun Young Rha; Chan Kim; Gun Min Kim; Sang Hyun Yoon; Ki Hyang Kim; Min Jae Kim; Joong Bae Ahn; Hyun Cheol Chung; Jae Kyung Roh; Hyo Song Kim
Journal:  Cancer Res Treat       Date:  2010-12-31       Impact factor: 4.679

6.  Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.

Authors:  Jason K Sa; Seung Won Choi; Junfei Zhao; Yeri Lee; Jing Zhang; Doo-Sik Kong; Jung Won Choi; Ho Jun Seol; Jung-Il Lee; Antonio Iavarone; Raul Rabadan; Do-Hyun Nam
Journal:  Int J Cancer       Date:  2019-01-07       Impact factor: 7.396

7.  Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer.

Authors:  Chan Kim; Hong Chon; Beodeul Kang; Kiyeol Kim; Hei-Cheul Jeung; Hyun Chung; Sung Noh; Sun Rha
Journal:  BMC Cancer       Date:  2013-08-23       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.